Sab biotherapeutics announces u.s. fda grants breakthrough therapy designation to sab-176 influenza immunotherapy

Sab-176 has now received both breakthrough and fast track designations from fda – signifying its potential to fundamentally improve influenza treatment and prophylaxis
SABS Ratings Summary
SABS Quant Ranking